Literature DB >> 15894078

The selective dopamine D3 receptor antagonist SB-277011-A attenuates ethanol consumption in ethanol preferring (P) and non-preferring (NP) rats.

Panayotis K Thanos1, John M Katana, Charles R Ashby, Michael Michaelides, Eliot L Gardner, Christian A Heidbreder, Nora D Volkow.   

Abstract

The mesolimbic dopamine (DA) system plays an important role in mediating addiction to alcohol and other drugs of abuse. Recent evidence points toward the role of the DA D3 receptor (D3R) in drug-induced reward, drug-taking, as well as cue-, drug-, and stress-triggered relapse to drug-seeking behavior. Accordingly, the present study examined the effects of acute selective antagonism of the D3R on ethanol consumption in alcohol Preferring (P) and Non-Preferring (NP) rats. We employed the two-bottle choice paradigm to monitor ethanol consumption in these rats before and after treatment with 3, 10, and 30 mg/kg (i.p.) of the selective D3R antagonist SB-277011-A. Results indicated a significant attenuation in ethanol preference, intake and lick responses in P rats treated with 10 and 30 mg/kg SB-277011-A. A similar, though not as robust effect was observed in ethanol consumption in the NP rats when treated with 30 mg/kg SB-277011-A. Finally, the acute administration of SB-277011-A did not produce extrapyramidal side effects, as indicated by stable lick response-volume ratios and lick response time distributions. These results further support the notion that the D3R is important in mediating the addictive properties of alcohol and suggest that selective blockade of the D3R may constitute a new and useful target for prospective pharmacotherapeutic approaches to alcoholism.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15894078     DOI: 10.1016/j.pbb.2005.03.013

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  35 in total

1.  Selectivity and activation of dopamine D3R from molecular dynamics.

Authors:  Zhiwei Feng; Tingjun Hou; Youyong Li
Journal:  J Mol Model       Date:  2012-07-03       Impact factor: 1.810

2.  Effects of A₂A adenosine receptor blockade or stimulation on alcohol intake in alcohol-preferring rats.

Authors:  Maria Vittoria Micioni Di Bonaventura; Carlo Cifani; Catia Lambertucci; Rosaria Volpini; Gloria Cristalli; Rino Froldi; Maurizio Massi
Journal:  Psychopharmacology (Berl)       Date:  2011-08-11       Impact factor: 4.530

3.  The selective dopamine D3 receptor antagonist SB-277011A reduces nicotine-enhanced brain reward and nicotine-paired environmental cue functions.

Authors:  Arlene C Pak; Charles R Ashby; Christian A Heidbreder; Maria Pilla; Jeremy Gilbert; Zheng-Xiong Xi; Eliot L Gardner
Journal:  Int J Neuropsychopharmacol       Date:  2006-08-31       Impact factor: 5.176

Review 4.  The role of central dopamine D3 receptors in drug addiction: a review of pharmacological evidence.

Authors:  Christian A Heidbreder; Eliot L Gardner; Zheng-Xiong Xi; Panayotis K Thanos; Manolo Mugnaini; Jim J Hagan; Charles R Ashby
Journal:  Brain Res Brain Res Rev       Date:  2005-07

Review 5.  Dopaminergic mechanism of reward-related incentive learning: focus on the dopamine D(3) receptor.

Authors:  R J Beninger; T J Banasikowski
Journal:  Neurotox Res       Date:  2008-08       Impact factor: 3.911

6.  Effects of chronic binge-like ethanol consumption on cocaine self-administration in rhesus monkeys.

Authors:  Paul W Czoty
Journal:  Drug Alcohol Depend       Date:  2015-05-21       Impact factor: 4.492

Review 7.  Rationale in support of the use of selective dopamine D₃ receptor antagonists for the pharmacotherapeutic management of substance use disorders.

Authors:  Christian Heidbreder
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2012-10-28       Impact factor: 3.000

8.  The effects of the preferential dopamine D(3) receptor antagonist S33138 on ethanol binge drinking in C57BL/6J mice.

Authors:  Onarae V Rice; Jay Patrick; Charles D Schonhar; Haoran Ning; Charles R Ashby
Journal:  Synapse       Date:  2012-06-20       Impact factor: 2.562

9.  Coupling Genetic Addiction Risk Score (GARS) and Pro Dopamine Regulation (KB220) to Combat Substance Use Disorder (SUD).

Authors:  Kenneth Blum; Margaret A Madigan; Lyle Fried; Eric R Braverman; John Giordano; Rajendra D Badgaiyan
Journal:  Glob J Addict Rehabil Med       Date:  2017-02-23

Review 10.  Animal models for medications development targeting alcohol abuse using selectively bred rat lines: neurobiological and pharmacological validity.

Authors:  Richard L Bell; Helen J K Sable; Giancarlo Colombo; Petri Hyytia; Zachary A Rodd; Lawrence Lumeng
Journal:  Pharmacol Biochem Behav       Date:  2012-07-25       Impact factor: 3.533

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.